Scholarlink

Background <p>The effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.</p> Methods <p>We retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.</p> Results <p>Six studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; <i>p</i> = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; <i>p</i> &lt; 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52–3.14; <i>p</i> = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; <i>p</i> = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; <i>p</i> = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; <i>p</i> = 0.620) in CRC.</p> Conclusions <p>Elevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Jichao Zhu,
  • Jiliang Zhang,
  • Chao Gu

摘要

Background

The effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.

Methods

We retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.

Results

Six studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; p = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; p < 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52–3.14; p = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; p = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; p = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; p = 0.620) in CRC.

Conclusions

Elevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.